Recent YSCC Discoveries

Yale Cancer Center researchers at Yale School of Medicine will present new research at the 46th annual San Antonio Breast Cancer Symposium (SABCS) from December 5 to 9.

A collaborative study led by Yale researchers reports the many gene expression changes that develop over the course of a neurodegenerative disorder called spinocerebellar ataxia type 1, shedding light on its progression.

The Winchester Center for Lung Disease (WCLD) opened in March 2021 at the North Haven Medical Center to improve access to exceptional care for more people with lung conditions. The expanded facilities at the Winchester Center have allowed expansion of subspecialized pulmonary care as well as access to a wide array of multidisciplinary services, more than what was possible at the original Winchester Chest Clinic (WCC) on Yale New Haven Hospital’s York Street Campus.

Trevor Sorrells, PhD, Assistant Professor and researcher at Yale School of Medicine, was recently named an inaugural Howard Hughes Medical Institute (HHMI) Freeman Hrabowski Scholar. This program celebrates and supports scientists with the potential to become great leaders in their field and create a more diverse and inclusive scientific environment.

The Yale Interventional Pulmonary team in Yale’s Section of Pulmonary, Critical Care, and Sleep Medicine (Yale-PCCSM) employs advanced technologies to diagnose and treat diseases in the chest, such as lung nodules and masses, lymph node enlargement, complex airways, and pleural effusions. The program, led by Kyle Bramley, MD, assistant professor of medicine (pulmonary), was one of the first interventional pulmonology programs in Connecticut when it was established in 2009. Today it remains the largest interventional pulmonary service in the state.

This inaugural event marked the launch of the Cancer Metabolism Initiative (CAMI), which aims to bring together investigators from across the campus to shape the future of cancer metabolism.

Yale Diabetes Research Center Soliciting Grant Applications

A new study finds that neuroinflammation and blood-brain-barrier dysfunction are not likely drivers of the neuropsychiatric symptoms of Long COVID, giving researchers more clues in their quest to uncover what actually may be the culprit. This study is the first time researchers have tested a large cohort of people living with Long COVID for spinal fluid markers of brain inflammation and blood-brain-barrier dysfunction.